Study M185

Study name

Hill MN 2008a

Title

Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report

Overall design

This study examined the endocannabinoids (anandamide; AEA) and 2-arachidonylglycerol (2-AG) in serum from ambulatory, medication-free female patients diagnosed with minor or major depression, and in controls matched for demographic characteristics. A total of 56 adult women participated in the study. Half of them met DSM-IV diagnostic criteria for clinical depression (n= 28); the other half had no lifetime history of psychiatric illness (n = 28). Depressed patients had to meet criteria for a current major depressive episode (n = 16) or minor depressive episode (n = 12) according to DSM-IV. Serum AEA and 2-AG were quantified using isotope-dilution, atmospheric pressure, chemical ionization liquid chromatography/mass spectrometry (LC-APCI-MS).

Study Type

Type1;

Data available

Unavailable

Organism

Human;

Categories of depression

Depressive disorder; Depression; Depression;

Criteria for depression

DSM-IV diagnosed major depressive episode or minor depressive episode

Sample size

56

Tissue

Peripheral; Blood; Serum;

Platform

MS-based; LC-MS: not reported;

PMID

18311684

DOI

10.1055/s-2007-993211

Citation

Hill MN, Miller GE, Ho WS, et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008;41(2):48-53.

Metabolite

MG(0:0/20:4(5Z,8Z,11Z,14Z)/0:0);

Anandamide;